Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.45 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSB | P07858 | 7/20 | 0.42 |
| ▸ | CTSH | P09668 | 5/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11239152 | 0.98 | CTSK (0.42) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL11231610 | 0.83 | CTSK (0.47) | CTSKCTSLCTSBCTSHCYP1A2 | |
| SCHEMBL192070 | 0.83 | CTSK (0.47) | CTSKCTSLCTSBCTSHCYP1A2 | |
| SCHEMBL191969 | 0.80 | CTSK (0.45) | CTSKCTSLCTSBCTSHCYP1A2 | |
| SCHEMBL15279313 | 0.79 | CTSK (0.45) | CTSKCTSLCTSBCTSH | |
| SCHEMBL16590926 | 0.79 | CTSK (0.45) | CTSKCTSLCTSBCTSH | |
| SCHEMBL9205347 | 0.78 | CYP1A2 (0.36) | CTSKCTSLCTSBCTSHCYP1A2 | |
| SCHEMBL16590939 | 0.77 | CTSK (0.42) | CTSKCTSLCTSBCTSHCYP1A2 | |
| SCHEMBL28997818 | 0.77 | CTSK (0.36) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL7516459 | 0.77 | CPN1 (0.39) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| EP-3037880-A1 | LAMINATE BODY | Fujifilm Corporation (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | CTSK 2950/4885CTSL 2958/4885CTSB 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.